KR20220151613A - 코로나바이러스 감염의 치료 - Google Patents

코로나바이러스 감염의 치료 Download PDF

Info

Publication number
KR20220151613A
KR20220151613A KR1020227029182A KR20227029182A KR20220151613A KR 20220151613 A KR20220151613 A KR 20220151613A KR 1020227029182 A KR1020227029182 A KR 1020227029182A KR 20227029182 A KR20227029182 A KR 20227029182A KR 20220151613 A KR20220151613 A KR 20220151613A
Authority
KR
South Korea
Prior art keywords
dosage form
sars
cov
virus
coronavirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227029182A
Other languages
English (en)
Korean (ko)
Inventor
드로어 벤-애셔
레자 파티
Original Assignee
레드힐 바이오파마 엘티디
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 레드힐 바이오파마 엘티디 filed Critical 레드힐 바이오파마 엘티디
Publication of KR20220151613A publication Critical patent/KR20220151613A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020227029182A 2020-03-10 2021-03-08 코로나바이러스 감염의 치료 Pending KR20220151613A (ko)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202062987429P 2020-03-10 2020-03-10
US62/987,429 2020-03-10
US202063003601P 2020-04-01 2020-04-01
US63/003,601 2020-04-01
US202063034817P 2020-06-04 2020-06-04
US63/034,817 2020-06-04
US202063074799P 2020-09-04 2020-09-04
US63/074,799 2020-09-04
US202063125427P 2020-12-15 2020-12-15
US63/125,427 2020-12-15
PCT/IB2021/000131 WO2021181157A1 (en) 2020-03-10 2021-03-08 Treatment of coronavirus infection

Publications (1)

Publication Number Publication Date
KR20220151613A true KR20220151613A (ko) 2022-11-15

Family

ID=76548186

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227029182A Pending KR20220151613A (ko) 2020-03-10 2021-03-08 코로나바이러스 감염의 치료

Country Status (11)

Country Link
US (6) US11052073B1 (https=)
EP (1) EP4117630A4 (https=)
JP (1) JP7822946B2 (https=)
KR (1) KR20220151613A (https=)
CN (2) CN117695284B (https=)
AU (1) AU2021235304A1 (https=)
BR (1) BR112022017923A2 (https=)
CA (1) CA3174438A1 (https=)
IL (1) IL295658A (https=)
MX (1) MX2022011173A (https=)
WO (1) WO2021181157A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210244705A1 (en) * 2020-02-07 2021-08-12 Centre For Digestive Diseases Therapeutic compositions, products of manufacture and methods for ameliorating or preventing coronavirus infection
CN117695284B (zh) 2020-03-10 2025-06-17 红山生物医药有限公司 冠状病毒感染的治疗
US11471448B2 (en) * 2020-12-15 2022-10-18 Redhill Biopharma Ltd. Sphingosine kinase 2 inhibitor for treating coronavirus infection in moderately severe patients with pneumonia
CN113398219A (zh) * 2021-06-30 2021-09-17 广州白云山星群(药业)股份有限公司 橘红痰咳浸膏在制备抑制人冠状病毒感染的药物中的用途
EP4286851A1 (en) 2022-06-01 2023-12-06 Universität Wien Methods and means for molecular characterization of post-viral fatigue syndrome
WO2025133697A2 (en) * 2023-12-20 2025-06-26 Redhill Biopharma Ltd. Combination therapy for inhibition of ebolavirus

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7342018B2 (en) 1998-07-20 2008-03-11 Wilex Ag Urokinase inhibitors and uses thereof
US6624169B1 (en) 1998-07-20 2003-09-23 Wilex Biotechnology Gmbh Urokinase inhibitors
AU9059798A (en) 1998-09-18 2000-04-10 Pentapharm Ag Urokinase inhibitors
DE50211672D1 (de) 2001-03-21 2008-03-27 Wilex Ag Urokinase-inhibitoren
CH695999A5 (de) 2002-02-28 2006-11-15 Wilex Ag Verfahren zur Herstellung von 3- Amidinophenylalanin-Derivaten.
WO2004011449A2 (de) 2002-07-25 2004-02-05 Wilex Ag Verfahren zur herstellung von phenylalanin-derivaten
DE10238048A1 (de) 2002-07-25 2004-02-05 Wilex Ag Verfahren zur Herstellung von Phenylalanin-Derivaten
US9770349B2 (en) * 2002-11-13 2017-09-26 University Of Virginia Patent Foundation Nanoporous stents with enhanced cellular adhesion and reduced neointimal formation
DE10323898A1 (de) 2003-05-26 2004-12-23 Wilex Ag Hydroxyamidin- und Hydroxyguanidin-Verbindungen als Urokinase-Hemmstoffe
RU2234313C1 (ru) 2003-06-04 2004-08-20 Кривошеин Юрий Семенович Средство инактивации коронавирусов
GB0420874D0 (en) 2004-09-20 2004-10-20 Swetree Technologies Ab Modulation of flowering time and growth cessation in perennial plants
DE102004045720A1 (de) 2004-09-21 2006-03-23 Wilex Ag Stabile Dosierungsform von Phenylalanin-Derivaten
BRPI0516106B1 (pt) 2004-10-14 2021-08-24 Wilex Ag Métodos para purificação e preparação de derivados de 3-hidroxiamidinofenilalanina, e para produção de derivados de 3-amidinofenilalanina
DE102004057195A1 (de) 2004-11-26 2006-06-01 Wilex Ag Kristalline Modifikationen von N-Alpha-(2,4,6-Triisopropylphenylsulfonyl)-3-hydroxyamidino-(L)-phenylalanin-4-ethoxycarbonylpiperazid und/oder Salzen davon
US8324237B2 (en) 2005-05-20 2012-12-04 Smith Charles D Methods for the treatment and prevention of inflammatory diseases
ES2528451T3 (es) 2005-06-17 2015-02-10 Apogee Biothechnology Corporation Inhibidores de esfingosina cinasa
WO2012166859A2 (en) * 2011-06-01 2012-12-06 The Curators Of The University Of Missouri Modulation of sphingosine 1-phosphate metabolizing enzymes for the treatment of negative-strand rna virus infections
WO2015161908A1 (en) * 2014-03-11 2015-10-29 Ludwig-Maximilians-Universität München Non-immunosuppressive cyclophilin inhibitors for the treatment of coronavirus infections
CA2965258C (en) * 2014-10-24 2023-09-19 Redhill Biopharma Ltd. Therapy for inhibition of single-stranded rna virus replication
DK3297438T3 (da) * 2015-05-21 2022-01-17 Chemocentryx Inc Ccr2-modulatorer
WO2017060771A2 (en) * 2015-10-06 2017-04-13 Redhill Biopharma Ltd. Combination therapies for treating cancer
US10195188B2 (en) * 2016-06-13 2019-02-05 Chemocentryx, Inc. Method of treating pancreatic cancer
US10251888B2 (en) * 2016-06-13 2019-04-09 Chemocentryx, Inc. Method of treating pancreatic cancer
DE102018217334A1 (de) * 2018-10-10 2020-04-16 Harbins Ruhr Bioscience, Inc. Sphingoid-Base und/oder Wirkstoff zur Verwendung bei der Prophylaxe und/oder Therapie einer viralen Infektion und/oder viralen Infektionskrankheit oder der Desinfektion, Nahrungsmittel/Nahrungsergänzungsmittel, Futtermittel/Futterergänzungsmittel und Pflanzenschutzmittel
CN117695284B (zh) * 2020-03-10 2025-06-17 红山生物医药有限公司 冠状病毒感染的治疗
EP4126234A1 (en) 2020-04-02 2023-02-08 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Compositions for coronavirus infection treatment and/or prevention

Also Published As

Publication number Publication date
US11918560B2 (en) 2024-03-05
CN117695284A (zh) 2024-03-15
IL295658A (en) 2022-10-01
US11052073B1 (en) 2021-07-06
US12551469B2 (en) 2026-02-17
CN115515560A (zh) 2022-12-23
US11045453B1 (en) 2021-06-29
JP2023517920A (ja) 2023-04-27
CN115515560B (zh) 2023-12-15
CN117695284B (zh) 2025-06-17
MX2022011173A (es) 2022-10-18
CA3174438A1 (en) 2021-09-16
US20240350461A1 (en) 2024-10-24
US20210299108A1 (en) 2021-09-30
US12502381B2 (en) 2025-12-23
AU2021235304A1 (en) 2022-10-06
EP4117630A1 (en) 2023-01-18
US11364227B2 (en) 2022-06-21
BR112022017923A2 (pt) 2022-10-18
EP4117630A4 (en) 2024-07-03
JP7822946B2 (ja) 2026-03-03
WO2021181157A1 (en) 2021-09-16
US20220031682A1 (en) 2022-02-03
US20210322390A1 (en) 2021-10-21

Similar Documents

Publication Publication Date Title
JP7822946B2 (ja) コロナウイルス感染の治療
CN116133657A (zh) 治疗covid-19疾病的新组合物和方法
US20230218596A1 (en) Methods involving neutrophil elastase inhibitor alvelestat for treating coronavirus infection
CN109789193A (zh) 使用间α抑制蛋白治疗肺病的方法
US20230151107A1 (en) Anti-cd6 antibody compositions and methods for treating and reducing negative effects of a coronavirus including covid-19
JP7840570B2 (ja) コロナウイルス感染症の処置のための方法
TW202320778A (zh) 新型冠狀病毒感染症治療劑
JP2023526200A (ja) ＳＡＲＳ－ＣｏＶ－２感染症の予防または治療のための適合溶質
RU2837859C1 (ru) Лечение коронавирусной инфекции
KR20230021009A (ko) 항바이러스 치료로서의 아젤라스틴
KR20230035522A (ko) 폐 염증 및 간질성 폐 질병을 치료하기 위한 레리글리타존
WO2021200651A1 (ja) コロナウイルス感染症治療剤
US12115150B2 (en) Biomarkers of coronavirus pneumonia
IL296066A (en) Compounds for use in the treatment of corona virus infection
RU2828013C1 (ru) Композиции антител к cd6 и способы лечения и снижения негативных последствий коронавируса, включая covid-19
WO2023192779A2 (en) Combined prevention and treatment of patients with respiratory diseases caused by rna viral infections
HK40096631A (zh) 用於治疗肺部炎症和间质性肺病的羟基吡格列酮

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902